Show simple item record

dc.contributor.authorRud, Ane Kristine Kongsgaard
dc.contributor.authorLund-Iversen, Marius
dc.contributor.authorBerge, Gisle
dc.contributor.authorBrustugun, Odd Terje
dc.contributor.authorSolberg, Steinar
dc.contributor.authorMælandsmo, Gunhild
dc.contributor.authorPedersen, Kjetil Boye
dc.date.accessioned2013-03-07T10:30:10Z
dc.date.available2013-03-07T10:30:10Z
dc.date.issued2012
dc.description.abstractThe metastasis-promoting protein S100A4 induces expression of ephrin-A1 and osteopontin in osteosarcoma cell lines. The aim of this study was to investigate S100A4-mediated stimulation of ephrin-A1 and osteopontin in non-small cell lung cancer (NSCLC) cell lines, and to characterize the expression of these biomarkers in primary tumor tissue from NSCLC patients. Four NSCLC cell lines were treated with extracellular S100A4, and ephrin-A1 and osteopontin expression was analyzed by real time RT-PCR and Western blotting. Immunohistochemical staining for S100A4, ephrin-A1 and osteopontin was performed on tissue microarrays containing primary tumor samples from a cohort of 217 prospectively recruited NSCLC patients, and associations with clinicopathological parameters were investigated. S100A4 induced ephrin-A1 mRNA and protein expression in adenocarcinoma, but not in squamous carcinoma cell lines, whereas the level of osteopontin was unaffected by S100A4 treatment. In primary tumors, moderate or strong immunoreactivity was observed in 57% of cases for cytoplasmic S100A4, 46% for nuclear S100A4, 86% for ephrin-A1 and 77% for osteopontin. Interestingly, S100A4 expression was associated with ephrin-A1 also in vivo, but there was no association between S100A4 and osteopontin. Expression levels of S100A4 and ephrin-A1 were significantly higher in adenocarcinomas compared to other histological subtypes, and S100A4-positive tumors were smaller and more differentiated than tumors without expression. Our findings suggest that S100A4, ephrin-A1 and osteopontin are involved in the biology of NSCLC, and further investigation of their potential use as biomarkers in NSCLC is warranted.
dc.identifier.citationBMC Cancer (2012) 12:333en
dc.identifier.cristinIDFRIDAID 965863
dc.identifier.doihttp://dx.doi.org/10.1186/1471-2407-12-333
dc.identifier.issn1471-2407
dc.identifier.urihttps://hdl.handle.net/10037/4903
dc.identifier.urnURN:NBN:no-uit_munin_4616
dc.language.isoengen
dc.publisherBioMed Centralen
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical molecular biology: 711en
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk molekylærbiologi: 711en
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Physiopathology: 721en
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Patofysiologi: 721en
dc.titleExpression of S100A4, ephrin-A1 and osteopontin in non-small cell lung canceren
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record